Jane Wolstenholme
BA(Hons) (London), MSc (York), PhD (Nottingham)
Senior Health Economist, HERC
Jane Wolstenholme has 20 years of experience of conducting economic evaluations for health policy makers and exploring methodological issues relating to the design and analysis of economic evaluations. She has been a health economist at HERC since 1998.
Her main interests include designing and conducting economic evaluations alongside trials and cost-effectiveness models. She is principal investigator and co-applicant on a wide variety of funded research projects, across a number of disease areas and health-care technologies, including cancer, chronic kidney disease, obesity, mental health, point of care diagnostics. She is a health economics advisor for the RDS South Central and for the NIHR Diagnostics Evidence Co-Operative, Oxford. She supervises MSc and DPhil students. Jane has published widely and is co-author of a major OUP text book ‘Applied Methods of Cost-effectiveness Analysis in Health Care’.
Recent publications
Proton beam therapy for oropharyngeal cancer (TORPEdO): a phase 3, randomised controlled trial.
Journal article
Thomson DJ. et al, (2026), Lancet
Supporting women with adherence to adjuvant endocrine therapy (SWEET): feasibility study of the HT&Me intervention.
Journal article
McGeagh L. et al, (2026), Eur J Oncol Nurs, 80
Cost Effectiveness of Local Anaesthetic Transperineal Versus Transrectal Biopsy: Results from the TRANSLATE Study.
Journal article
Little M. et al, (2025), Eur Urol Focus
Improving outcomeS for Women diagnosed with early breast cancer through adhErence to adjuvant Endocrine Therapy (SWEET): study protocol for a pragmatic randomised control trial of a patient-centred intervention to improve adherence to endocrine therapy in early breast cancer.
Journal article
McGeagh L. et al, (2025), Trials, 26
Systematic review of health economic models for assessment and diagnosis of dementia
Journal article
Kwon J. et al, (2025), Alzheimer's & Dementia: Behavior & Socioeconomics of Aging, 1
